Earnings summaries and quarterly performance for EXAGEN.
Executive leadership at EXAGEN.
Board of directors at EXAGEN.
Research analysts who have asked questions during EXAGEN earnings calls.
RO
Ross Osborn
Cantor Fitzgerald
5 questions for XGN
Also covers: AXGN, CERS, CVRX +12 more
KM
Kyle Mikson
Canaccord Genuity
4 questions for XGN
Also covers: AKYA, BDSX, CSTL +12 more
AB
Andrew Brackmann
William Blair & Company, L.L.C.
2 questions for XGN
Also covers: ADPT, AWH, BDSX +11 more
MB
Maggie Boeye
William Blair
2 questions for XGN
Also covers: QDEL, SERA, VCYT
Mark Massaro
BTIG, LLC
2 questions for XGN
Also covers: ADPT, AKYA, BLLN +19 more
WR
William Ruby
TD Cowen
2 questions for XGN
Also covers: BDSX, PACB, PSNL +1 more
DB
Dan Brennan
UBS
1 question for XGN
Also covers: A, ADPT, DHR +10 more
Daniel Brennan
TD Cowen
1 question for XGN
Also covers: A, ADPT, AVTR +24 more
Paul Knight
KeyBanc Capital Markets
1 question for XGN
Also covers: A, ATR, AZTA +14 more
Recent press releases and 8-K filings for XGN.
ExGen Resources Announces 2025 Southmore Exploration Results and MTB Metals Acquisition
XGN
New Projects/Investments
M&A
- ExGen Resources Inc. announced results from its 2025 exploration program on the Southmore Property in Northwest British Columbia, with a recent sample returning 32.9 g/t gold and 1.26 percent copper over 1 meter.
- A 3D DC-Resistivity and Induced Polarization (DCIP) Survey, conducted in October 2025, delineated a large high chargeability and conductivity anomaly at depth, suggesting a possible telescoping porphyry system.
- ExGen Resources acquired the Southmore property through the acquisition of MTB Metals on December 19, 2025.
- ExGen operates as a project accelerator, funding exploration and development through joint ventures and partnership agreements, and currently holds 9 exploration projects and 4 royalties.
1 day ago
ExGen Resources Inc. Secures Second Silver Stream on South American Gold Mine
XGN
New Projects/Investments
M&A
- ExGen Resources Inc. (XGN) entered a binding Letter of Intent (LOI) on December 19, 2025, to acquire a second silver stream on a past-producing gold mine in South America, which doubles its aggregate silver stream on the property.
- ExGen paid US$500,000 for a 33.3% silver stream on the first 333,333 ounces of silver produced and a 16.7% stream on additional silver, with a delivery price equal to 20% of the spot silver price.
- PrivateCo is required to deliver a minimum of 4,200 ounces of silver to ExGen each calendar quarter beginning in Q2 2027, with any shortfall made up by an equivalent value of gold.
- CEO Jason Riley commented that this transaction builds a "formidable foundation of potential future cash flow" and strategically positions ExGen to "capitalize on silver price momentum".
Dec 24, 2025, 10:24 PM
Exagen Reports Record Q3 2025 Revenue and Provides 2025 Guidance
XGN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Exagen (XGN) reported Q3 2025 revenue of $17.2 million, marking its highest quarter in history and a nearly 40% increase over Q3 2024. Year-to-date revenue through Q3 2025 reached approximately $50 million, representing 19% growth.
- The company's trailing twelve-month Average Selling Price (ASP) for CTD increased 9% year-over-year to $441. However, ASP expansion is slower than anticipated due to new biomarker reimbursement not ramping quickly and the loss of a large high-ASP direct bill account.
- Exagen successfully launched assays for anti PAD4 antibodies at the end of Q3 2025, further differentiating its rheumatoid arthritis offering. While billing for PAD4 began, no revenue was reflected in Q3 as payment history had not yet been established.
- The Pharma and CRO business generated nearly $800,000 in revenue in Q3 2025, contributing to a year-to-date total of $1.2 million, with an order backlog of $3.5 million.
- Exagen ended Q3 2025 with $35.7 million in cash and cash equivalents. The company maintains its full-year 2025 revenue guidance of $65 million to $70 million, though sustained cash flow positivity may be pushed to 2026 due to ASP challenges.
Nov 4, 2025, 1:30 PM
Exagen Reports Record Q3 2025 Revenue and Volume Growth
XGN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Exagen reported record Q3 2025 revenue of $17.2 million, marking a 40% increase over Q3 2024, and achieved 19% year-to-date revenue growth to approximately $50 million.
- Volume growth was strong, with Q3 2025 CTD test volume up 15% year-over-year and over 8% year-to-date.
- The trailing 12-month Advise CTD test Average Selling Price (ASP) increased 9% year-over-year to $441, though ASP acceleration was slower than expected due to new biomarker reimbursement and the loss of a high-ASP direct bill account.
- Exagen successfully launched Anti-PAD4 antibodies at the end of Q3 2025, its second novel set of rheumatoid arthritis biomarkers this year.
- The company maintained its full-year revenue guidance of $65 million-$70 million but indicated that sustained cash flow positivity might be delayed until 2026 due to ongoing ASP challenges.
Nov 4, 2025, 1:30 PM
Exagen Inc. Reports Strong Q3 2025 Results
XGN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Exagen Inc. reported record total revenue of $17.2 million for the third quarter of 2025, marking a 38% increase compared to the same period in 2024.
- The company's net loss for Q3 2025 was $(7.1) million, with an Adjusted EBITDA of $(1.9) million.
- As of September 30, 2025, Exagen held $35.7 million in cash and cash equivalents, an increase from $30.0 million in the second quarter of 2025.
- Exagen reiterated its full-year 2025 revenue guidance of $65 million to $70 million and anticipates achieving positive adjusted EBITDA in the fourth quarter of 2025 at the high end of this revenue range.
- Operational highlights include a 16% growth in AVISE CTD test volume and an expanded AVISE CTD trailing twelve-month average selling price (ASP) of $441 per test.
Nov 4, 2025, 1:03 PM
Exagen Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance
XGN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Exagen Inc. reported record total revenue of $17.2 million for Q3 2025, representing a 38% increase compared to the third quarter of 2024.
- The company ended Q3 2025 with $35.7 million in cash and cash equivalents.
- For Q3 2025, Exagen reported a net loss of $(7.087) million and an Adjusted EBITDA of $(1.895) million.
- Exagen reiterated its 2025 full-year revenue guidance of between $65 million and $70 million, with an expectation to achieve positive adjusted EBITDA in Q4 2025 at the high end of the revenue range.
- AVISE CTD test volume grew 16% compared to Q3 2024, and the trailing twelve-month average selling price (ASP) expanded to $441 per test.
Nov 4, 2025, 1:00 PM
Quarterly earnings call transcripts for EXAGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more